Sarepta Therapeutics Enters Material Agreement
Ticker: SRPT · Form: 8-K · Filed: Aug 29, 2025 · CIK: 873303
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Sarepta inked a big deal, expect financial moves.
AI Summary
On August 28, 2025, Sarepta Therapeutics, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The company, incorporated in Delaware, is involved in the pharmaceutical preparations industry.
Why It Matters
This filing signals a significant new contract or financial commitment for Sarepta Therapeutics, potentially impacting its financial obligations and strategic direction.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce financial and operational risks for the company.
Key Players & Entities
- Sarepta Therapeutics, Inc. (company) — Registrant
- August 28, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 2834 (industry_code) — Standard Industrial Classification
FAQ
What type of material definitive agreement did Sarepta Therapeutics, Inc. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on August 28, 2025.
What is the nature of the financial obligation created by Sarepta Therapeutics?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but does not provide specific details.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on August 28, 2025.
What is Sarepta Therapeutics, Inc.'s Standard Industrial Classification code?
Sarepta Therapeutics, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
In which state is Sarepta Therapeutics, Inc. incorporated?
Sarepta Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 1,617 words · 6 min read · ~5 pages · Grade level 13 · Accepted 2025-08-29 16:18:38
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SRPT NASDAQ Glo
- $700.0 million — eto agreed to exchange with the Company $700.0 million in aggregate principal amount of Existi
- $602.0 million — hem for consideration consisting of (i) $602.0 million in aggregate principal amount of 4.875%
- $123.3 million — and (iii) an aggregate of approximately $123.3 million in cash. The New Convertible Notes we
- $1,000 — t as provided for in the Indenture) per $1,000 principal amount of New Convertible Not
- $60.00 — itial conversion price of approximately $60.00 per share of Common Stock), representin
- $20.58 — reported sale price of Common Stock of $20.58 per share on August 20, 2025. Prior t
- $150.0 million — tanding New Convertible Notes, at least $150.0 million aggregate principal amount of New Conve
- $18 — rs LLC at a purchase price per share of $18.07, equal to the last reported sale pri
Filing Documents
- d945054d8k.htm (8-K) — 35KB
- d945054dex41.htm (EX-4.1) — 606KB
- g945054g0828232916762.jpg (GRAPHIC) — 2KB
- g945054g0828232917035.jpg (GRAPHIC) — 2KB
- g945054g0828232917252.jpg (GRAPHIC) — 2KB
- g945054g0828232917453.jpg (GRAPHIC) — 2KB
- g945054g0828232917641.jpg (GRAPHIC) — 2KB
- g945054g0828232917886.jpg (GRAPHIC) — 3KB
- 0001193125-25-192794.txt ( ) — 902KB
- srpt-20250828.xsd (EX-101.SCH) — 3KB
- srpt-20250828_lab.xml (EX-101.LAB) — 17KB
- srpt-20250828_pre.xml (EX-101.PRE) — 11KB
- d945054d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sarepta Therapeutics, Inc. By: /s/ Ian Estepan Ian Estepan President and Chief Operating Officer Date: August 29, 2025